GIANT CELL ARTERITIS
Clinical trials for GIANT CELL ARTERITIS explained in plain language.
Never miss a new study
Get alerted when new GIANT CELL ARTERITIS trials appear
Sign up with your email to follow new studies for GIANT CELL ARTERITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New injection aims to tame dangerous blood vessel inflammation
Disease control CompletedThis study tested if adding a medication called secukinumab to a standard steroid taper helps people with newly diagnosed giant cell arteritis stay in remission longer. It involved 151 adults whose disease symptoms were under control. The goal was to see if the drug could delay o…
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New scan aims to spot Blindness-Causing inflammation earlier
Diagnosis CompletedThis study tested a new type of digital PET/CT scan to see if it could accurately diagnose giant cell arteritis (GCA), a serious condition that inflames arteries and can lead to sudden blindness. Researchers compared the new scan to a standard ultrasound in 92 patients suspected …
Matched conditions: GIANT CELL ARTERITIS
Sponsor: Jewish General Hospital • Aim: Diagnosis
Last updated Mar 31, 2026 12:12 UTC
-
New scan could replace painful biopsy for common artery disease
Diagnosis CompletedThis study tested if a PET/CT scan could accurately diagnose giant cell arteritis (GCA), a common artery inflammation in people over 50. It compared the scan's accuracy to other imaging tests and the current standard, which is an invasive biopsy. The goal was to find a less painf…
Matched conditions: GIANT CELL ARTERITIS
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Diagnosis
Last updated Mar 16, 2026 15:27 UTC
-
Common drug tested for hidden power against debilitating autoimmune symptoms
Symptom relief CompletedThis study tested whether a very low dose of an existing medication (naltrexone) could improve daily life for people with several types of vasculitis, a group of autoimmune diseases that cause blood vessel inflammation. The trial involved 60 adults whose disease was stable but wh…
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Apr 03, 2026 14:42 UTC
-
First look: testing a new IV treatment for painful inflammatory diseases
Knowledge-focused CompletedThis study aimed to understand how the body processes a drug called secukinumab when given through an IV (intravenous) line, and to check its safety. It involved 65 adults with either giant cell arteritis (GCA) or polymyalgia rheumatica (PMR), two painful inflammatory conditions.…
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Mar 17, 2026 13:08 UTC